Proteases are enzymes that hydrolyze peptide bonds in proteins and peptides; thus, they
control virtually all biological processes. Our understanding of protease function has …

Abstract The European Organisation for Research and Treatment of Cancer Quality of Life
Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess …

Multiple myeloma management has undergone profound changes in the past thanks to
advances in our understanding of the disease biology and improvements in treatment and …

DNA alterations have been extensively reported in multiple myeloma (MM); however, they
cannot yet fully explain all the biological and molecular abnormalities in MM, which remains …

Background Multiple myeloma (MM) is an incurable cancer with complex treatment options.
Trusting patient–clinician relationships are essential to promote effective shared decision …

Background Serum free light chain assay (SFLCA) and κ/λ ratio, and protein electrophoretic
methods are used in the diagnosis and monitoring of monoclonal gammopathies. Methods …

Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the
treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal …

Interferon-α (IFNα) has been prescribed to effectively treat multiple myeloma (MM) and other
malignancies for decades. Its use has waned in recent years, however, due to significant …

The unfolded protein response is responsible for the detection of misfolded proteins and the
coordination of their disposal and is necessary to maintain the cellular homoeostasis …

Objectives Achieving complete response (CR) has been linked to improved progression‐
free (PFS) and overall (OS) survival in myeloma. A meta‐analysis was conducted to …